デフォルト表紙
市場調査レポート
商品コード
1316815

中枢神経系バイオマーカー市場:適応疾患別、用途別、エンドユーザー別-2023-2030年の世界予測

Central Nervous System Biomarkers Market by Disease Indication, Application, End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 184 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.96円
中枢神経系バイオマーカー市場:適応疾患別、用途別、エンドユーザー別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

中枢神経系バイオマーカーの世界市場は、2023年に43億7,418万米ドル、CAGR 10.32%で大きく成長し、2030年には87億3,877万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の中枢神経系バイオマーカー市場を評価するために不可欠です。事業戦略や製品満足度などの主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客ベース、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展:有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化:新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向:COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報:主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション:将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします:

1.中枢神経系バイオマーカーの世界市場規模および予測は?

2.予測期間中、世界の中枢神経系バイオマーカー市場を形成するCOVID-19の阻害要因と影響は?

3.中枢神経系バイオマーカーの世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は?

4.中枢神経系バイオマーカーの世界市場における競争戦略は?

5.中枢神経系バイオマーカーの世界市場における技術動向と規制の枠組みは?

6.中枢神経系バイオマーカーの世界市場における主要ベンダーの市場シェアは?

7.中枢神経系バイオマーカーの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 神経疾患を引き起こす肥満の増加
      • 中枢神経系バイオマーカーの臨床使用の可能性
      • ゲノミクス、プロテオミクス、イメージングシステムの開発
    • 抑制要因
      • 高額な検証コストと不利な償還コスト
    • 機会
      • 中枢神経系バイオマーカーの研究開発活動の改善
      • 戦略的提携の構築と新製品と技術のイントロダクション新たな焦点が当てられる
    • 課題
      • 熟練した技術専門家の不足
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 中枢神経系バイオマーカー市場:疾患適応症別

  • アルツハイマー病
  • 多発性硬化症
  • パーキンソン病
  • 外傷性脳損傷

第7章 中枢神経系バイオマーカー市場:用途別

  • 診断
  • 病気のリスク評価
  • 創薬と開発
  • 個別化医療

第8章 中枢神経系バイオマーカー市場:エンドユーザー別

  • クリニックと病院
  • 診断研究所
  • 研究センター

第9章 南北アメリカの中枢神経系バイオマーカー市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の中枢神経系バイオマーカー市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの中枢神経系バイオマーカー市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ分析:主要企業別

第13章 掲載企業一覧

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2030 (%)
  • FIGURE 5. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 6. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 7. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET DYNAMICS
  • FIGURE 9. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 5. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 10. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY CLINICS & HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 146. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 147. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET LICENSE & PRICING
目次
Product Code: MRR-450A0628CED4

The Global Central Nervous System Biomarkers Market is forecasted to grow significantly, with a projected USD 4,374.18 million in 2023 at a CAGR of 10.32% and expected to reach a staggering USD 8,738.77 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Central Nervous System Biomarkers Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Central Nervous System Biomarkers Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease Indication, market is studied across Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, and Traumatic Brain Injury. The Alzheimer's Disease is projected to witness significant market share during forecast period.

Based on Application, market is studied across Diagnostics, Disease Risk Assessment, Drug Discovery & Development, and Personalized Medicines. The Drug Discovery & Development is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Clinics & Hospitals, Diagnostic Labs, and Research Centers. The Diagnostic Labs is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Central Nervous System Biomarkers Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Central Nervous System Biomarkers Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Central Nervous System Biomarkers Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Central Nervous System Biomarkers Market?

4. What is the competitive strategic window for opportunities in the Global Central Nervous System Biomarkers Market?

5. What are the technology trends and regulatory frameworks in the Global Central Nervous System Biomarkers Market?

6. What is the market share of the leading vendors in the Global Central Nervous System Biomarkers Market?

7. What modes and strategic moves are considered suitable for entering the Global Central Nervous System Biomarkers Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Central Nervous System Biomarkers Market, by Disease Indication, 2022 vs 2030
  • 4.3. Central Nervous System Biomarkers Market, by Application, 2022 vs 2030
  • 4.4. Central Nervous System Biomarkers Market, by End-User, 2022 vs 2030
  • 4.5. Central Nervous System Biomarkers Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in obesity leading to neurological illnesses
      • 5.1.1.2. Availability of central nervous system biomarkers for clinical use
      • 5.1.1.3. Development of genomics, proteomics, and imaging systems
    • 5.1.2. Restraints
      • 5.1.2.1. High validation cost and unfavorable reimbursement costs
    • 5.1.3. Opportunities
      • 5.1.3.1. Improving research and development activities for central nervous system biomarkers
      • 5.1.3.2. Emerging focus on building strategic alliances and introduction of new products and technology
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled technical professionals
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Central Nervous System Biomarkers Market, by Disease Indication

  • 6.1. Introduction
  • 6.2. Alzheimer's Disease
  • 6.3. Multiple Sclerosis
  • 6.4. Parkinson's Disease
  • 6.5. Traumatic Brain Injury

7. Central Nervous System Biomarkers Market, by Application

  • 7.1. Introduction
  • 7.2. Diagnostics
  • 7.3. Disease Risk Assessment
  • 7.4. Drug Discovery & Development
  • 7.5. Personalized Medicines

8. Central Nervous System Biomarkers Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinics & Hospitals
  • 8.3. Diagnostic Labs
  • 8.4. Research Centers

9. Americas Central Nervous System Biomarkers Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Central Nervous System Biomarkers Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Central Nervous System Biomarkers Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing